3,5-二氯-2-羟基苯甲酰胺 | 17892-26-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氯-2-羟基苯甲酰胺
• 英文名称: 3,5-dichloro-2-hydroxybenzamide
• 英文别名: 3,5-dichloro-2-hydroxy-benzoic acid amide；3,5-Dichlor-2-hydroxy-benzoesaeure-amid；3.5-Dichlor-2-hydroxy-benzamid；3.5-Dichlor-salicylsaeure-amid；3,5-dichlorosalicylamide
• CAS: 17892-26-1
• 化学式: C₇H₅Cl₂NO₂
• 分子量: 206.028
• InChiKey: DUCPHOYOSFRQJX-UHFFFAOYSA-N

物化性质

• 沸点：
  267.3±40.0 °C(Predicted)
• 密度：
  1.579±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3,5-二氯-2-羟基苯甲酰胺 在 硫酸 、 potassium carbonate 、 溶剂黄146 、 丁酮 、 sodium iodide 、 sodium nitrite 作用下， 生成 3,5-dichloro-2-(2-oxo-2H-chromen-3-ylmethoxy)-benzoic acid
  参考文献：
  名称：

  The Effect of Changes in the Allyl Group on the Rearrangement of Allyl Ethers of Salicylic Acids

  摘要：

  DOI：

  10.1021/ja01148a026
• 作为产物：
  描述：

  3,5-二氯-2-羟基苯甲酰氯 在 Ammonium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以23%的产率得到3,5-二氯-2-羟基苯甲酰胺
  参考文献：
  名称：

  Discovery and Structure–Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG)

  摘要：

  The metabolism of poly(ADP-ribose) (PAR) in response to DNA strand breaks, which involves the concerted activities of poly(ADP-ribose) polymerases (PARPs) and poly(ADP-ribose) glycohydrolase (PARG), modulates cell recovery or cell death depending upon the level of DNA damage. While PARP inhibitors show high promise in clinical trials because of their low toxicity and selectivity for BRCA related cancers, evaluation of the therapeutic potential of PARG is limited by the lack of well-validated cell permeable inhibitors. In this study, target-related affinity profiling (TRAP), an alternative to high-throughput screening, was used to identify a number of druglike compounds from several chemical classes that demonstrated PARG inhibition in the low-micromolar range. A number of analogues of one of the most active chemotypes were synthesized to explore the structure activity relationship (SAR) for that series. This led to the discovery of a putative pharmacophore for PARG inhibition that contains a modified salicylanilide structure. Interestingly, these compounds also inhibit PARP-1, indicating strong homology in the active sites of PARG and PARP-1 and raising a new challenge for development of PARG specific inhibitors. The cellular activity of a lead inhibitor was demonstrated by the inhibition of both PARP and PARG activity in squamous cell carcinoma cells, although preferential inhibition of PARG relative to PARP was observed. The ability of inhibitors to modulate PAR metabolism via simultaneous effects on PARPs and PARG may represent a new approach for therapeutic development.

  DOI：

  10.1021/jm200325s

文献信息

• Continuous-Flow Hofmann Rearrangement Using Trichloroisocyanuric Acid for the Preparation of 2-Benzoxazolinone
  作者：Guido Gambacorta、Ian R. Baxendale

  DOI：10.1021/acs.oprd.1c00440

  日期：2022.2.18

  A continuous-flow preparation of 2-benzoxazolinone via the Hofmann rearrangement of salicylamide has been implemented employing trichloroisocyanuric acid as the stable and atom-economic chlorinating agent. The system was optimized to avoid solid accumulation and allow the preparation of hundreds of grams of the pure desired material over a working day. Furthermore, a trichloroisocyanuric acid (TCCA)-based

  使用三氯异氰脲酸作为稳定的原子经济氯化剂，通过水杨酰胺的霍夫曼重排连续流动制备 2-苯并恶唑啉酮。该系统经过优化，可避免固体堆积，并允许在一个工作日内制备数百克纯所需材料。此外，基于三氯异氰尿酸 (TCCA) 的 2-苯并恶唑酮氯化反应生成相应的 5-氯衍生物也在分批条件下进行。
• Certain benzoxazoles and the use thereof as metal extractants
  申请人：General Mills Chemicals, Inc.

  公开号：US04020081A1

  公开（公告）日：1977-04-26

  Benzoxazoles having the structure ##STR1## where R is hydrogen or an alkyl group having from 1 to 20 carbon atoms, R' is hydrogen, chlorine or an alkyl group containing from 1 to 20 carbon atoms, X is H or Chlorine and the total number of carbon atoms in R and R' is 6 to 40 with the proviso that one of R and R' must be an alkyl group of at least 6 carbon atoms. The benzoxazoles are useful in a process of recovering metal values, particularly copper and nickel, from aqueous solutions thereof.

  具有以下结构的苯并噁唑##STR1##其中R是氢或具有1到20个碳原子的烷基，R'是氢，氯或含有1到20个碳原子的烷基，X是H或氯，R和R'中碳原子的总数为6到40，但必须保证R和R'中至少有一个是至少含有6个碳原子的烷基。这些苯并噁唑在从其水溶液中回收金属价值，特别是铜和镍的过程中是有用的。
• Phenol derivatives and their use as rotamase inhibitors
  申请人：Knolle Jochen

  公开号：US20070054904A1

  公开（公告）日：2007-03-08

  The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z 1 , Z 2 , Z 3 and Z 4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR 10 —, —C(S)—NR 11 —, —C(N—CN)—NR 12 —, —S(O)—, —S(O 2 )—, —S(O)—NR 13 —, and —S(O 2 )—NR 14 —, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y. is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl, substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及以下化合物的公式(I)、(II)、(III)、(IV)、(V)： 其中，Z1、Z2、Z3和Z4分别且独立地选自包括C(O)、-C(S)-、-C(O)-NR10-、-C(S)-NR11-、-C(N-CN)-NR12-、-S(O)-、-S(O2)-、-S(O)-NR13-和-S(O2)-NR14-、-O-、-S-的基团，或者它们各自单独不存在；X是一个间隔符，可以独立地选自-M1-L1-K-L2-M2-的基团，其中Y选自包括烷基、取代烷基、直链烷基、取代直链烷基、支链烷基、取代支链烷基、直链烯基、取代直链烯基、支链烯基、取代支链烯基、直链炔基、取代直链炔基、支链炔基、取代支链炔基、环烷基、取代环烷基、环烯基、取代环烯基、杂环基、取代杂环基、单不饱和杂环基、多不饱和杂环基、单取代多不饱和杂环基、多取代多不饱和杂环基、单取代单不饱和杂环基、多取代单不饱和杂环基、芳基、取代芳基、杂芳基和取代杂芳基，其中Y不同于肽或不存在。
• COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF
  申请人：KNOLLE Jochen

  公开号：US20110065760A1

  公开（公告）日：2011-03-17

  The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z 1 , Z 2 , Z 3 and Z 4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR 10 —, —C(S)—NR 11 —, —C(N—CN)—NR 12 —, —S(O)—, —S(O 2 )—, —S(O)—NR 13 —, and S(O 2 )—NR 14 —, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y. is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl, substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及一种式（I），（II），（III），（IV），（V）的化合物：其中Z1，Z2，Z3和Z4分别独立地选自包括C（O）—，—C（S）—，—C（O）—NR10—，—C（S）—NR11—，—C（N—CN）—NR12—，—S（O）—，—S（O2）—，—S（O）—NR13—和S（O2）—NR14—，—O—，—S—或各自缺席的基团；X是间隔基团，独立地选自包括-M1-L1-K-L2-M2-，其中Y选自包括烷基，取代烷基，直链烷基，取代直链烷基，支链烷基，取代支链烷基，直链烯基，取代直链烯基，支链烯基，取代支链烯基，直链炔基，取代直链炔基，支链炔基，取代支链炔基，环烷基，取代环烷基，环烯基，取代环烯基，杂环基，取代杂环基，单不饱和杂环基，多不饱和杂环基，单取代多不饱和杂环基，多取代多不饱和杂环基，单取代单不饱和杂环基，多取代单不饱和杂环基，芳基，取代芳基，杂芳基和取代杂芳基，其中Y不同于肽或不存在。
• New compounds for the inhibition of rotamases and use thereof
  申请人：Jerini AG

  公开号：EP2100876A2

  公开（公告）日：2009-09-16

  The present invention is related to a compound of the formula (I): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising - C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -S(O)-, -S(O2)-, -S(O)-NR13-, and -S(O2)-NR14-, -O-, -S- or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl , substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及一种式 (I) 的化合物： 其中 Z1、Z2、Z3 和 Z4 各自独立地选自包括 -C(O)-、-C(S)-、-C(O)-NR10-、-C(S)-NR11-、-C(N-CN)-NR12-、-S(O)-、-S(O2)-、-S(O)-NR13- 和 -S(O2)-NR14-、-O-、-S- 或各自独立地不存在的组；X 是间隔物，独立地选自包括-M1-L1-K-L2-M2-在内的组，其中 Y 选自包括烷基、取代烷基、直链烷基、取代直链烷基、支链烷基、取代支链烷基、直链烯基、取代直链烯基、支链烯基、取代支链烯基、直链炔基、取代直链炔基、支链炔基、取代支链炔基、环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、环烷基、取代环烷基、环烯基、取代环烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代的多不饱和杂环基、单取代的单不饱和杂环基、多取代的单不饱和杂环基、芳基、取代的芳基、杂芳基和取代的杂芳基，其中 Y 不同于肽或不存在。